Mimran A, Targhetta R, Laroche B
Nouv Presse Med. 1981 Apr 30;10(19):1579-82.
The angiotensin I-converting enzyme inhibitor, captopril (SQ 14225) was proposed as first treatment in 12 cases of uncomplicated essential hypertension maintained on unrestricted sodium intake (group I). Arterial pressure was normalized in 7 patients (subgroup Ia) whilst hydrochlorothiazide was added to captopril in 5 patients (subgroup Ib). A significant dose-response curve between the dose of captopril (range 75 to 450 mg/day) and the antihypertensive effect was obtained with a maximum at 300 mg/day. In 8 patients (group II) hydrochlorothiazide was proposed first and the addition of captopril was necessary in 4 cases. No relationship between pretreatment PRA and the maximum effect of captopril was observed (r = -0.34, NS). No disturbance of upright blood pressure regulation was noted. Adverse reaction consisted of 4 cases of benign and spontaneously regressive skin rash or pruritus.
血管紧张素I转换酶抑制剂卡托普利（SQ 14225）被提议作为12例单纯原发性高血压患者的初始治疗药物，这些患者钠摄入不受限制（I组）。7例患者（Ia亚组）的血压恢复正常，而5例患者（Ib亚组）在卡托普利基础上加用了氢氯噻嗪。卡托普利剂量（75至450毫克/天）与降压效果之间呈现显著的剂量反应曲线，300毫克/天时效果最佳。8例患者（II组）首先使用氢氯噻嗪，4例患者需要加用卡托普利。未观察到治疗前血浆肾素活性（PRA）与卡托普利最大效应之间存在相关性（r = -0.34，无显著性差异）。未发现直立性血压调节障碍。不良反应包括4例良性且可自发消退的皮疹或瘙痒。
